

**DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY**

<b>Rapid Alert Notification of a Quality Defect / Recall</b>	
Meldende Stelle: Regierungspräsidium Darmstadt Luisenplatz 2 64283 Darmstadt	
1. To / Empfänger:	FAX
<input checked="" type="checkbox"/> Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)	0228-207-3515
<input type="checkbox"/> Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)	01888/412-2303
<input type="checkbox"/> Paul-Ehrlich-Institut - Bundesamt für Sera und Impfstoffe - (PEI)	06103/77-1234
<input checked="" type="checkbox"/> Oberste Landesgesundheitsbehörde: Hessisches Sozialministerium	0611/817-3850
2. Product Recall Class of Defect:    I <u>II</u> (circle one)	3. Counterfeit / Fraud (specify)*
4. Product: Cephazolin Fresenius 2g	5. Marketing Authorisation Number: <b>6062403.00.00</b> For use in humans
6. Brand/Trade Name: Cephazolin Fresenius 2g	7. INN or Generic Name: Cefazolin
8. Dosage Form:	9. Strength: 2 g
10. Batch/Lot Number: C3443	11. Expiry Date: 11/2009
12. Pack size and Presentation: 100 ml Vials	13. Date Manufactured: 12.11. – 14.11.2007
14. Marketing Authorisation Holder: Fresenius Kabi Deutschland GmbH, Else Kröner-Straße 1, 61346 Bad Homburg v.d.H	
15. Manufacturer†: Fresenius Kabi Deutschland GmbH Contact Person: Dr. Andrea Bauer (or Marcus Metternich) Telephone: ++49 6172 686 8512 (or - 7313)	16. Recalling Firm (if different):  Contact Person:  Telephone:
17. Recall Number Assigned (if available)	

18. Details of Defect/Reason for Recall: Underfilling		
19. Information on distribution including exports (type of customer, e.g. hospitals): Hospital pharmacies, wholesalers, pharmacies		
20. Action taken by Issuing Authority:		
21. Proposed Action: Recall of the batch C3443		
22. From (Issuing Authority): Regierungspräsidium Darmstadt Luisenplatz 2 64283 Darmstadt		23. Contact Person: Dr. Lenze Telephone: 06151/12-5066
24. Signed: Dr. Lenze	25. Date: 05.03.2008	26. Time:

\* Information not required, when notified from outside EU.

† The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has released the batch in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

*This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you*